63 
S. 1217, however, sets a bad precedent for future restrictive regu- 
lation of biomedical research in general. The compliance provisions 
and paperwork are excessive, possibly unworkable, and particularly 
burdensome for small businesses. The potential for obstructing re- 
search and impeding progress in conquering diseases appears to be 
much greater than the benefits accruing to the public through the 
provisions of this legislation. 
[ 803 ] 
